A Multicenter, Prospective, Observational Real-World Study of Bushen Tongluo Decoction for the Treatment of Rheumatoid Arthritis

The Affiliated Hospital of Gansu Traditional Medicine University0 个研究点开始时间: 待定最近更新: 2024年5月29日

适应症

试验速览

暂无简介。

•(1) Meets the aforementioned Western medical diagnosis, traditional Chinese disease classification, and syndrome diagnosis.
•(2) Age range between 35 and 60 years.
•(3) Classified with joint function levels I, II, or III, and hand X-ray staging falls under stages I, II, or III.
•(4) RA disease activity is mild to moderate.
•(5) Has not recently taken or been administered non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs (DMARDs), biologics, glucocorticoids, or similar medications intended to alleviate symptoms or improve rheumatoid arthritis condition.

•(1) Patients who do not meet the diagnostic criteria.
•(2) Patients who have used glucocorticoid medications continuously for more than one month in the last six months (such as oral prednisone, methylprednisolone, or intravenous methylprednisolone).
•(3) Patients with concomitant other rheumatic diseases.
•(4) Patients who have taken medications in the past year that promote bone formation or absorption, such as calcium supplements, calcitriol, or teriparatide.
•(5) Patients with acute cardiovascular or cerebrovascular diseases.
•(6) Patients with significant concurrent systemic diseases, severe trauma, planned surgery, or severe infections.
•(7) Patients with a history of drug abuse, allergies to the medications used in this study, or a history of mental illness.
•(8) Women who are pregnant, breastfeeding, or in the preconception period.

发起方

The Affiliated Hospital of Gansu Traditional Medicine University